Menu

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

Equipping Healthcare Professionals with the Necessary Tools for Improving Care in Ovarian Cancer

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Examining Novel Approaches in the Management of Acute and Chronic GVHD

Wednesday, January 19, 2022, 12:00 PM - 1:00 PM CT
Register to attend January 19  
 

 

Activity Description

Modern management of acute and chronic graft-vs-host disease (GVHD) has been dramatically transformed by the approval and continued investigation of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib and the Janus kinase (JAK) inhibitor ruxolitinib in steroid-refractory chronic and acute GVHD. In this regard, expert guidance is needed to aid in integration of these agents into current algorithms to optimize clinical outcomes. Other innovative novel strategies are poised to enter into GVHD care, including T-cell costimulation blocking agents (abatacept), alpha-1 antitrypsin, Rho-associated coiled-coil kinase 2 (ROCK2) inhibitors, serine protease inhibitors, and anti-integrin monoclonal antibodies.

Pharmacists and nurses can benefit from education on the latest scientific developments in the management and prevention of GVHD, including steroid-naïve and steroid-refractory disease, and will benefit from the perspectives of experts in the field to formulate up-to-date clinical management strategies and provide optimal patient care. The goal of this activity is to improve the knowledge and competence of pharmacists and nurses in treating patients with hematologic malignancies with or at risk of developing GVHD.

Target Audience

The target audience is pharmacists, including specialty pharmacists and other pharmacists who care for patients with hematologic malignancies with or at risk of developing GVHD. In addition, the target audience includes nurses across the continuum, pharmacy directors, chief pharmacy officers, health plan administrators, health-systems, group purchasing organizations, and other stakeholders in specialty pharmacy.

Learning Objectives

After completing the activity, participants should be able to:

  • Describe the pathophysiology of GVHD and its implications on the use of novel therapies for the treatment of patients with or at risk of developing GVHD.
  • Analyze current and emerging clinical trial data evaluating the use of recently FDA-approved agents for acute, chronic, steroid-naive, or steroid-refractory GVHD.
  • Identify adverse events associated with prophylactic and therapeutic strategies for GVHD and discuss best practice management of these adverse events.

Faculty

Eno Inyang, PharmD, BCPS, BCOP
Stem Cell Transplant Clinical Pharmacy Specialist
Pharmacy Department, Dana-Farber Cancer Institute
Boston, MA

Marissa Olson, PharmD, BCOP
Clinical Pharmacy Specialist Hematologic Malignancies/Bone Marrow Transplant
Pharmacy, Barnes-Jewish Hospital
Saint Louis, MO

CME/CE Accreditation

ACPE Credit Designation (Pharmacist CE)

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-006-L01-P has been assigned to this live knowledge-based activity (initial release date 1-19-22). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
 


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Eno Inyang, PharmD, BCPS, BCOP, does not have any relevant conflicts of interest to report. Marissa Olson, PharmD, BCOP, does not have any relevant conflicts of interest to report.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Funding

This activity is supported by an educational grant from Incyte Corporation.

 

Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.